Figure 2. Patient inclusion schematic for demographic and outcomes analyses.

219 patients were evaluable for demographic and survival analyses and 71 patients were both seropositive and had serial draws and thus could be included in recurrence analyses. An additional 43 patients were seropositive at diagnosis but excluded from survival analyses due to lack of a follow-up draw (38 patients), inability to receive definitive therapy (4 patients), or recurrence prior to first draw (1 patient).